Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Researchers use AI to reveal sex-based differences in glioblastoma prognosis

For years, cancer researchers have noticed that more men than women get a lethal form of brain cancer called glioblastoma.

7 Oct 2024

New technique offers real-time glioblastoma monitoring

A new study shows the potential power of imaging paired with radiation to shape treatment for glioblastoma patients in real time.

1 Oct 2024

Discovery of cyclotide from violets enhances glioblastoma chemotherapy

Glioblastoma is one of the most serious brain diseases known. More than 45% of brain cancers are gliomas.

30 Sep 2024

Innovative CAR-T cells effectively target glioblastoma with reduced toxicity

Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective.

26 Sep 2024

Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the treatment of glioblastoma. Vortioxetine, an antidepressant, showed promising anti-glioblastoma activity, significantly reducing tumor size in preclinical trials.

24 Sep 2024

Promising antidepressant offers hope for glioblastoma treatment

Glioblastoma is a particularly aggressive brain tumor that at present is incurable. Cancer doctors can extend patients' life expectancy through operations, radiation, chemotherapy or surgical interventions. Nevertheless, half of patients die within twelve months of diagnosis.

20 Sep 2024

Fibrous scars drive glioblastoma recurrence

A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surgery, and immunotherapy.

11 Sep 2024

Carcinotech dominates summer awards season

Over the past six years, Carcinotech has been laser-focused on developing, optimising and commercializing our innovative drug development platform.

From Carcinotech 30 Aug 2024

16 promising postdoctoral scientists awarded Damon Runyon Fellowships for cancer research

The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

28 Aug 2024

Novel biochip diagnoses deadly brain cancer in under an hour

Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis.

28 Aug 2024

Engineered NK cells with IL-21 show strong antitumor activity against glioblastoma

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research from The University of Texas MD Anderson Cancer Center.

12 Aug 2024

Study links renalase-1 and T-cell receptor interaction to increased melanoma survival

A new research paper was published in Oncotarget's Volume 15 on August 5, 2024, entitled, "Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival."

8 Aug 2024

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).

8 Aug 2024

Decoding glioblastoma: New insights into molecular subtypes and mesenchymal transition mechanisms

Glioblastoma multiforme (GBM) stands as a formidable adversary in oncology, characterized by its molecular complexity and relentless progression.

7 Aug 2024

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA).

7 Aug 2024

Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

6 Aug 2024

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.

5 Aug 2024

Glioblastoma News and Research

Further Reading